You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
步長製藥(603858.SH)擬放棄控股子公司浙江華派3.98%股權優先受讓權
格隆匯 12-24 16:50

格隆匯 12 月 24日丨步長製藥(603858.SH)公佈,公司於2020年12月23日召開了第三屆董事會第三十七次會議,審議通過了《關於擬放棄優先受讓控股子公司股權暨關聯交易的議案》,南京華爾派生物技術有限公司(“南京華爾派”)擬以447.1萬元交易價格將其持有的浙江華派生物醫藥有限公司(“浙江華派”)3.98%股權轉讓給杭州環和盛創生物醫藥科技合夥企業(有限合夥)(“杭州環和”),公司同意放棄優先受讓權。

公司此次放棄優先受讓權,是基於對公司長期發展戰略和實際經營情況的整體考慮。放棄優先受讓權後,公司持有浙江華派的股權比例不變,控股權未發生變化,不改變公司合併報表範圍,不會對上市公司財務狀況和經營成果產生不利影響,不存在損害公司和全體股東,特別是中小股東利益的情況。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account